TCI GENE Inc.
TCI GENE Inc., together with its subsidiaries, provides genetic testing and assessment services in Taiwan and Mainland China. It operates through Inspection and Consumable Products segments. The company offers memory, anti-aging, health management, child growth and development, nutritional metabolism and absorption, OB weight management, and SC skin management genetic testing; gut microbiota test… Read more
TCI GENE Inc. (6879) - Total Liabilities
Latest total liabilities as of June 2025: NT$178.51 Million TWD
Based on the latest financial reports, TCI GENE Inc. (6879) has total liabilities worth NT$178.51 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
TCI GENE Inc. - Total Liabilities Trend (2021–2024)
This chart illustrates how TCI GENE Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
TCI GENE Inc. Competitors by Total Liabilities
The table below lists competitors of TCI GENE Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Imugene Limited
PINK:IUGNF
|
USA | $38.56 Million |
|
Zenvia Inc
NASDAQ:ZENV
|
USA | $930.11 Million |
|
Terrain Minerals Ltd
AU:TMX
|
Australia | AU$566.54K |
|
VisDynamics Holdings Bhd
KLSE:0120
|
Malaysia | RM6.09 Million |
|
Melewar Industrial Group Bhd
KLSE:3778
|
Malaysia | RM181.72 Million |
|
TVA Group Inc
PINK:TVAGF
|
USA | $220.69 Million |
|
Scandinavian Real Heart AB (Publ)
F:7820
|
Germany | €13.59 Million |
|
Salarius Pharmaceuticals Inc
NASDAQ:SLRX
|
USA | $1.85 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down TCI GENE Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.74 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how TCI GENE Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for TCI GENE Inc. (2021–2024)
The table below shows the annual total liabilities of TCI GENE Inc. from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$101.29 Million | -34.88% |
| 2023-12-31 | NT$155.55 Million | +8.65% |
| 2022-12-31 | NT$143.17 Million | -15.50% |
| 2021-12-31 | NT$169.44 Million | -- |